References
- SendtKVTracyDKBhattacharyyaSA systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disordersPsychiatry Res20152251–2143025466227
- PerkinsDOAdherence to antipsychotic medicationsJ Clin Psychiatry199960Suppl 212530
- MontesJMMaurinoJde DiosCMedinaESuboptimal treatment adherence in bipolar disorder: impact on clinical outcomes and functioningPatient Prefer Adherence20137899423378745
- American Psychiatric AssociationPractive Guidelines for the Treatment of Patients with Schizophrenia2nd edWashington, DCAmerican Psychiatric Association2004
- CaseiroOPerez-IglesiasRMataIPredicting relapse after a first episode of non-affective psychosis: a three-year follow-up studyJ Psychiatr Res20124681099110522721546
- XiaoJMiWLiLShiYZhangHHigh relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People’s Republic of ChinaNeuropsychiatr Dis Treat2015111161116726056450
- WeidenPJKozmaCGroggALocklearJPartial compliance and risk of rehospitalization among California Medicaid patients with schizophreniaPsychiatr Serv200455888689115292538
- KinonBJHillALLiuHKollack-WalkerSOlanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophreniaInt J Neuropsychopharmacol2003629710212890301
- CzekallaJWagnerTSchachtAKlugeMKinonBEffectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patientsPatient Prefer Adherence20071192719956444
- ChuePJonesBTaylorCCDicksonRDissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophreniaCan J Psychiatry200247877177412420656
- BitterITreuerTDilbazNPatients’ preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover studyWorld J Biol Psychiatry201011789490320653494
- SanLCasillasMCiudadAGilaberteIOlanzapine orally disintegrating tablet: a review of efficacy and complianceCNS Neurosci Ther200814320321418801113
- MontgomeryWTreuerTKaragianisJAscher-SvanumHHarrisonGOrally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other propertiesPatient Prefer Adherence2012610912522346347
- BarnettPGScottJYRosenheckRAGroupCSPSHow do clinical trial participants compare to other patients with schizophrenia?Schizophr Res20111301–3343921514794
- KraemerSChartierFAugendre-FerranteBEffectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational studyHum Psychopharmacol201227328429422473831
- NovickDMontgomeryWTreuerTAguadoJKraemerSHaroJMComparative effectiveness in terms of treatment discontinuation of orodispersable versus standard oral olanzapine tablets in non-adherent patients: results from a 1-year European Outpatient Observational StudyValue Health2014177A766
- NovickDMontgomeryWTreuerTAguadoJKraemerSHaroJMRelationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational studyBMC Psychiatry20151518926239486
- SpearingMKPostRMLeverichGSBrandtDNolenWModification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BPPsychiatry Res19977331591719481807
- HaroJMKamathSAOchoaSThe Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand Suppl2003416162312755850
- ThompsonKKulkarniJSergejewAAReliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychosesSchizophr Res200042324124710785582
- LamWYFrescoPMedication adherence measures: an overviewBiomed Res Int2015201521704726539470